Skip to main content
placeholder image

A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.

Journal Article


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2019

Citation


  • Kotasek, D., Coward, J., de Souza, P. L., Underhill, C., Jin, X., Li, B., . . . Prawira, A. (2019). A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.. Journal of Clinical Oncology, 37(15_suppl), e14006. doi:10.1200/jco.2019.37.15_suppl.e14006

Web Of Science Accession Number


Start Page


  • e14006

End Page


  • e14006

Volume


  • 37

Issue


  • 15_suppl

Place Of Publication


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2019

Citation


  • Kotasek, D., Coward, J., de Souza, P. L., Underhill, C., Jin, X., Li, B., . . . Prawira, A. (2019). A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.. Journal of Clinical Oncology, 37(15_suppl), e14006. doi:10.1200/jco.2019.37.15_suppl.e14006

Web Of Science Accession Number


Start Page


  • e14006

End Page


  • e14006

Volume


  • 37

Issue


  • 15_suppl

Place Of Publication